Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam

Clinical Microbiology and Infection

Volumn 25, Issue 6, 2019, Pages 763.e5-763.e8

  Galani, I ^a   Antoniadou, A ^a   Karaiskos, I ^b   Kontopoulou, K ^c   Giamarellou, H ^b   Souli, M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c Aristotle University and Hippokration General Hospital   (Greece)

Author keywords

Carbapenem resistant Enterobacteriaceae; Carbapenemase; KPC mutations; Meropenem vaborbactam; Porin deficiency

Indexed keywords

AMIKACIN; AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; CARBAPENEMASE; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DORIPENEM; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN OMPK35; OUTER MEMBRANE PROTEIN OMPK36; PIPERACILLIN PLUS TAZOBACTAM; PORIN; PROTEIN VARIANT; SULTAMICILLIN; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE; BETA LACTAMASE INHIBITOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; ESCHERICHIA COLI; GENE MUTATION; GENOMICS; GREECE; HYDROLYSIS; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PLASMID; PRIORITY JOURNAL; TRANSPOSON; WHOLE GENOME SEQUENCING; BACTERIAL GENOME; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CEFTAZIDIME; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; GENOME, BACTERIAL; GENOMICS; GREECE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; WHOLE GENOME SEQUENCING;

EID: 85064272236     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2019.03.011     Document Type: Article

References (15)

1. Galani, I., Karaiskos, I., Karantani, I., Papoutsaki, V., Maraki, S., Papaioannou, V., et al. Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016. Euro Surveill, 23, 2018, 1700775.
2. Doménech-Sánchez, A., Martínez-Martínez, L., Hernández-Allés, S., del Carmen Conejo, M., Pascual, A., Tomás, J.M., et al. Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother 47 (2003), 3332–3335.
3. Kaczmarek, F.M., Dib-Hajj, F., Shang, W., Gootz, T.D., High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe. Antimicrob Agents Chemother 50 (2006), 3396–3406.
4. García-Fernández, A., Miriagou, V., Papagiannitsis, C.C., Giordano, A., Venditti, M., Mancini, C., et al. An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. Αntimicrob Agents Chemother 54 (2010), 4178–4184.
5. Sherry, N., Howden, B., Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam - epidemiology, laboratory detection and treatment implications. Expert Rev Anti Infect Ther 16 (2018), 289–306.
6. Humphries, R.M., Hemarajata, P., Resistance to ceftazidime-avibactam in Klebsiella pneumoniae due to porin mutations and the increased expression of KPC-3. Antimicrob Agents Chemother, 61, 2017 e00537-17.
7. Shields, R.K., Chen, L., Cheng, S., Chavda, K.D., Press, E.G., Snyder, A., et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne bla(KPC-3) mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother, 61, 2017 e02097-16.
8. Giddins, M.J., Macesic, N., Annavajhala, M.K., Stump, S., Khan, S., McConville, T.H., et al. Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in bla(KPC-2)-Harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother 62 (2018), e02101–e02117.
9. Gaibani, P., Campoli, C., Lewis, R.E., Volpe, S.L., Scaltriti, E., Giannella, M., et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother 73 (2018), 1525–1529.
10. KPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum beta-lactamases. Antimicrob Agents Chemother, 61, 2017 e02534–16.
11. Docquier, J.D., Mangani, S., An update on β-lactamase inhibitor discovery and development. Drug Resist Updat 36 (2018), 13–29.
12. Mehta, S.C., Rice, K., Palzkill, T., Natural variants of the KPC-2 carbapenemase have evolved increased catalytic efficiency for ceftazidime hydrolysis at the cost of enzyme stability. PLoS Pathog, 11, 2015, e1004949.
13. Hidalgo-Grass, C., Warburg, G., Temper, V., Benenson, S., Moses, A.E., Block, C., et al. KPC-9, a novel carbapenemase from clinical specimens in Israel. Antimicrob Agents Chemother 56 (2012), 6057–6059.
14. Gartzonika, K., Rossen, J.W.A., Sakkas, H., Rosema, S., Priavali, E., Friedrich, A.W., et al. Identification of a KPC-9-producing Klebsiella pneumoniae ST258 cluster among KPC-2-producing isolates of an ongoing outbreak in Northwestern Greece: a retrospective study. Clin Microbiol Infect 24 (2018), 558–560.
15. Both, A., Büttner, H., Huang, J., Perbandt, M., Belmar Campos, C., Christner, M., et al. Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate. J Antimicrob Chemother 72 (2017), 2483–2488.